Discover a new adventure

Seek President and CEO. Quantitative Radiology Solutions (QRS) (doing business as Quantaras) provides body-wide analysis of medical images to personalize cancer treatment decisions. Our unique Automatic Anatomy Recognition (AAR) software supports recognition and analysis of anatomical objects and diseased tissue in multiple body regions using MRI, CT, and PET/CT images. Our first application aims to reduce side effects for cancer patients undergoing radiation therapy, and the application has been validated at 4 academic medical centers. QRS received FDA clearance for this application in April 2021. The management team at QRS combines business, product development and industry experience to systematically de-risk innovations and bring regulatory cleared products to the market.

VitalCore

Carnegie Mellon University

VitalCore is a Medical Devices Integration (MDI) solution that provides an integrated platform for showing the status, error messages, and patient info stored across all devices in various hospitals. VitalCore provides a visualized form of status data for easier comprehension and viewership by using tables, bar graphs, line charts, pie charts, and donut charts that enable the users to grasp the trend of the data and generate insights efficiently to improve patient care and reduce costs. Compared to similar device connectivity monitoring providers, VitalCore is focused on medical devices and has an active pilot that provides both an HL7 viewer and mobile application for healthcare professionals on the go. VitalCore is looking to expand their leadership team as they prepare to fundraise.

Rubitection

Rubitection is developing a skin health and wellness system to improve assessment and care management of dermatological, plastic surgery, and vascular conditions with an initial application to early bedsores detection. Bedsores are an $11 billion healthcare problem at affects 2.3 million each year killing 60K. If detected early they can be prevented, but low cost early detection tools are not available. Our Rubitect Assessment System (RAS) empowers any caregiver in hospitals, nursing homes, and in home care to detect bedsore early and support care management. Rubitection’s issued patents, and exclusive worldwide license provide barriers to competitors. The RAS’ low risk FDA pathway allows a quick path to a $4.1 billion US bedsore market. Two recurring revenues supports long term sustainability. Within 5 - 6 years of product launch, Rubitection will generate $48 million in sales using a hybrid sales model. Rubitection will exit through acquisition to a wound care company like Hill-Rom, or 3M.

MCDx - methylation cytometry diagnostics

Brown University

Overview DNA methylation-based biomarkers have great potential to transform the diagnosis, monitoring, and treatment of cancer and other diseases. DNA methylation is an epigenetic mechanism used by cells to control gene expression. During DNA methylation, methyl groups are added to the DNA molecule, changing the DNA activity but not the sequence. Errors in methylation have been linked to a variety of diseases. Currently, clinicians use DNA methylation tests to screen for certain genetic changes that can affect processes such as methionine metabolism and hormone balance. Market Opportunity Few DNA methylation-based biomarkers have been successfully translated into clinical practice. There is limited technology to assess epigenetic information cost effectively at a large scale. Leukocytes, or white blood cells, mount the immune response to pathogens and foreign antigens. Until now, the distribution of leukocytes has been determined by examination under a microscope or with a flow cytometer.

EncapBio Systems

Cell replacement therapies hold tremendous promise for type 1 diabetes, hemophilia, lysosomal storage diseases and other cellular disorders. EncapBio Systems has developed technologies for safe and functional delivery of cell therapies ready for pre-clinical development. Most of our recent work, ranging from material synthesis and device fabrication to cell engineering and process integration, has been centered around the goal of successfully delivering safely insulin producing cells with long-term function for T1D patients. EncapBio Systems builds upon 10 years of research of high quality proof-of-concept publications and patent applications. EncapBio Systems is seeking co-founders and investors to help build the next biomaterial platform for cell therapy.

Reach Neuro

University of Pittsburgh

Stroke is an incredibly pervasive problem that directly affects one quarter of the world’s population. Unfortunately, many of these people are told they will never regain functional use of their arm or hand. With Reach, they will. One of our patients was able to cut food with a fork and knife and feed herself for the first time in 9 years since having her stroke. In contrast to existing assistive tools such as functional electrical stimulation, Reach’s device allows the user full control over complex and naturalistic movements. Advantages of the technology: • Assists movements in all upper limb joints • Restores naturalistic and voluntary movements • Immediate improvements • Assists users in performing tasks of daily living • Eligible for chronic stroke patients even years after their stroke • Uses standard implant device and surgical procedure • Does not require donning and doffing bulky equipment

PionEar Technologies

Harvard University

Ear infections are the number on cause of doctors visits worldwide, affecting 700 million people each year. Chronic ear infections are often treated with the insertion of a tympanostomy tube into the ear drum. While these help to drain fluid, they often come with complications which can result in follow up surgeries and hearing loss. The PionEar tympanostomy tube technology addresses the most common complications by changing the geometry and materials of the tube to enhance fluid transport and reduce the chances of biofilm formation.

StraDEFY

George Washington University

Peritoneal carcinomatosis is a late stage manifestation of colon and ovarian cancer with a poor prognosis. Intraperitoneal (IP) chemotherapy is effective, but current methods lead to toxicity, which is not easily tolerated by patients. We propose a new approach, in which the chemotherapy drug is encapsulated in bioadhesive nanoparticles (BNPs) that can be delivered locally by established IP infusion methods. These BNPs are retained for many days in the IP space, and slowly release chemotherapy drugs, maximizing effectiveness, while minimizing toxicity.

Nanochon

Knee cartilage injuries in young active people have unique challenges that do not face older patients. The treatments need to be able to withstand intense activity and last for years. There is currently no gold standard treatment, with all solutions having significant drawbacks in price, recovery time, and/or longevity of treatment. Nanochon has developed a 3D printed synthetic cartilage replacement which is inserted with minimally invasive surgery and encourages new tissue growth, extending the lifetime of the treatment.

ClostraBio

University of Chicago

ClostraBio is a preclinical-stage pharmaceutical company creating new medicines to treat diseases resulting from intestinal barrier dysfunction, especially those caused by shifts to the microbiome. ClostraBio's first indications are in the treatment and prevention of food allergy, initially peanut allergy, and ClostraBio recently began a program in colitis. ClostraBio has licensed a proprietary drug delivery platform, developed by the ClostraBio co-founders, from the University of Chicago and are using this platform for oral delivery of small molecules and metabolites derived from the microbiome to the GI tract. ClostraBio's founding scientific team are key opinion leaders and world's experts in food allergy, the microbiome, immunology and immuno-engineering, drug delivery, and polymer chemistry. ClostraBio is seeking a Chief Executive Officer and Chief Medical Officer.

ProteoWise

ProteoWise was founded by a seasoned team of scientists from the Strittmatter Laboratory at Yale University which has a history of commercialization of innovations emerging from the lab. ProteoWise aims to unlock the protein world. Its technology will disrupt the protein analysis industry by enabling researchers to move beyond the current Western Blot standard and into easy, high-throughput bench-top proteomics.

SNTF Diagnostics

SNTF Diagnostics is a diagnostic for predicting brain damage and long-term dysfunction after a concussion. Mild traumatic brain injury (mTBI) is a common neurological injury, affecting over 1.5 million people in the US annually, as well as thousands of military personnel. Currently, there are no proven therapies for mitigating brain damage and improving the long-term outcome of mTBI. Dr. Siman discovered that the blood level of SNTF peptide identifies mTBI patients that are likely to have white matter structural damage and persistent brain dysfunction.

NextGenET

University of Pittsburgh

Ventilator Associated Pneumonia (VAP) is viewed as an inevitable consequence of long-term ventilator support rather than a preventable infection. In fact, VAP develops in 1 out of 3 intubated patients in intermediate care units. Along with the high prevalence, VAP has an average mortality rate of almost 50%. As a result, hospitals utilize procedural steps to prevent VAP in patients (such as head elevation and maintaining oral hygiene), but these actions fail to adequately prevent the root cause of VAP which is that current endotracheal (ET) tubes, or breathing tubes, do not create a long-term and effective seal in the trachea to prevent bacteria from entering the lungs. These tubes fail to create a proper seal because they employ an inflatable cuff that (1) deflates over time, (2) does not maintain consistent contact with the airway surface, and (3) is susceptible to shifting position with every patient movement. These design flaws allow harmful bacteria to pass the cuff and enter the lungs of patients.

RiboRupt Biotech

We have applied a unique, robust, and comprehensive image-based assay developed in our laboratory to discover small molecule inhibitors of nucleolar function. Results from pilot screens on FDA-approved drugs reveal 83 unique hits that include known and putative antineoplastic agents.

ProTech Sensors

Volatile organic compounds (VOCs) are carbon containing molecules that have low boiling points and high vapor pressures causing them to evaporate into gas phase at ambient conditions. A wide range of VOC analysis devices are used in various industries for occupational exposure monitoring, environmental monitoring, process control, detection of explosive compounds, and medical diagnosis. Gas chromatography mass spectrometry (GCMS) is the gold standard method for analysis of VOCs. However, these systems are bulky, expensive, and sophisticated laboratory instruments that require skilled professionals for operation. ProTech’s VOCSense is a sensor-based analysis technology that resembles the functionality of a gas chromatography mass spectrometry system. VOCSense can identify and quantify individual VOCs from normal air samples. ProTech is looking for a C-level leader and advisors to support them during development and fundraising.

Aperiam Bio

While deep learning methods exist to guide protein optimization, examples of novel proteins generated with these techniques require a priori mutational data. Aperiam is taking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry. We have trained a portfolio of computer vision algorithms on protein chemistry and use those algorithms to mutate genes for improved catalysis, expression, stability, and solubility. We are now using this approach to build our own suite of stabilized and solubilized enzyme therapeutics for direct delivery to the lung via nebulization and in parallel tailoring the computer vision framework to antibodies for expedited development and improved manufacturability.

BEXORG

Existing brain perfusion systems are focused on preserving immediately harvested organs until transplantation. These systems are not applicable to research and development applications where the organs may not be immediately obtained postmortem. OrganEx has developed an effective method to salvage organs ex-vivo to advance clinical research and transplantation studies.

Powernet

Stanford researchers have developed an architecture and control scheme for the coordination of distributed energy resources (DER), such as solar and storage, to minimize operation cost, enhance network reliability, and provide DER aggregation. The availability of electric load and generation data in electric grids varies both spatially and temporally due to: the random nature of loads and renewable generation; distributed locations of the loads and DER; and communication delays. Stanford researchers have found that control schemes that utilize local information (within the firmware of the storage unit, or in a home automation appliance) and delayed information to a global controller (e.g., collected from smart meter readings) perform near the ideal, but unimplementable, theoretical limit of performance.

Exolva Therapeutics

University of California, Davis

Moving Therapeutic Proteins Into the Cytosol and Nucleus. Exolva is using CPMPs (cell-permeant miniature proteins) to deliver therapeutic enzymes and gene-editing tools to correct inborn genetic disease. CPMPs are small, folded proteins that contain a specific array of five Arg residues on an ⍺-helix backbone. CPMPs can reach cytosol and nucleus with efficiencies as high as 75%. CPMPs possess many advantages relative to previous, purported ‘cell-penetrating peptides’, including low toxicity, high and tunable stability, enzyme cargo retains enzymatic activity, among other features.

VasoBio

VasoBio is startup company focusing on vascular disease treatment & medical devices. VasoBio has developed a proprietary ligand-based coating technology, VasoCoat, to improve vascular grafts and other blood contacting devices. Our technology overcomes the major barriers of currently available vascular grafts and possesses optimal functionality. The current focus of VasoBio is to apply VasoCoat to improve patency of hemodialysis vascular graft and reduce thrombosis, stenosis, and infection.

ResponseGels

Brown University

The continuous emergence and rapid spread of antibiotic resistant bacteria and antimicrobial resistant Candida has caused serious environmental and public health issues worldwide due to increasing difficulty in treating infections. Triggered drug delivery systems that limit exposure to antibacterials and/or antimicrobials can alleviate these challenges and help prevent resistance. We have developed responsive hydrogel systems to combat skin wound bacterial and fungal infections. ResponseGels is developing hydrogels that incorporate a degradable peptide sequence in the backbone that responds specifically to either 𝛽‐lactamases (βLs), the most common cause of resistance to antibiotics, or aspartic proteases (Saps) secreted by virulent Candida.

Think Bioscience

University of Colorado

Pharma companies have increasingly relied on innovative biotech startups to bolster their pipeline. The global small-molecule drug discovery market reached $25B in 2019 and is expected to grow to $50B by 2027. Think's business model is to partner with pharma companies to build precisely targeted, readily synthesizable molecules. For a drug target of interest, standard partnership models consist of an upfront fee with long-term development milestones and royalties. Just for the SHP2 (similar class to PTP1B) market, there have been several partnerships with deal values exceeding $500M. Synthetic biology is a growing field that designs microbes to confer capabilities outside their native function. Proof-of-concept has been demonstrated in elusive target, PTP1B, which is implicated in type 2 diabetes, obesity, and breast cancer. Further development will focus on optimizing the two novel drug scaffolds and expanding the platform to other key protein classes.

Aepnus Technology

University of California, Berkeley

Maintaining and expanding lithium cell and battery manufacturing capability here in America—as well as in allied and partner countries—is critical to national security and is essential to developing resilient defense supply chains not under threat from near-peer adversaries. Based on engineering research conducted at UC Berkeley, Aepnus’ electrochemical technology platform reduces the cost to refine industrially relevant salts such as lithium, manganese, and potash by 70%, with far less environmental impact. By electrifying mineral refinement trains, we enable domestic production of these materials and position the US as a leader in the global production of battery minerals. Combining modular flow reactors and state-of-the-art electrode formulations (hardware) with thermodynamic optimization models (software), Aepnus will decarbonize the lithium-ion battery value chain and enable low-cost US domiciled refinement of critical battery minerals.

SmartScan2

Case Western Reserve University

SmartScan2 is revolutionizing secure identification applications with unclonable polymer film-based, scalable technology. Most, if not all security devices in use today can be corrupted, counterfeited, or easily interpreted. Examples of these devices include personal identification cards, passports, pharmaceutical product tracking, currency, and product identification tags. One good example of this corruption involves credit cards. The fifty year old “magnetic strip” technology on a credit card has been corrupted by the use of illegal credit card “skimmers” attached to the credit card readers, and reported in the local news as prevalent on gas pumps and ATMs. The newer “chip” technology on credit cards can also be corrupted by the use of credit card skimmers which are becoming more prevalent in similar locations. SmartScan2's ID security is “unclonable” since it is vastly more difficult to corrupt, counterfeit or interpret the relevant information.

Carrisan Technologies

University of California, Davis

Foodborne illness is a significant health and economic problem globally. Cross-contamination of food by pathogens via surfaces of food processing equipment is a leading risk factor in foodborne disease outbreaks. Antimicrobial coatings that make food contact surfaces self-sanitizing have potential to reduce cross-contamination and represent a $2.3B market opportunity. Despite that promise, the antimicrobial coating technology available for food contact surface applications is severely limited by a lack of food-grade coatings, lack of efficacy in high volume/organic matter environments, difficult application, high cost and challenges in use with legacy equipment. We have developed novel antimicrobial coatings to make food contact surfaces self-sanitizing to prevent cross-contamination. The coatings are made of food-grade, FDA GRAS materials. They are safe, effective, low-cost, environmentally friendly and useable on legacy equipment. The underlying technology was developed at University of California-Davis.

Rhenium Chemotherapeutics

About half of treated cancer patients receive platinum-based drugs (eg. cisplatin, carboplatin) alone or in co-administration with other anticancer agents. Despite their efficacy, their use is limited by toxic side effects and inherent or acquired resistance to platinum-based drugs by tumor cells. To address this challenge, a Cornell team lead by Prof. Justin Wilson have developed rhenium-based chemotherapeutics for treatment of platinum-resistant cancers.

Photon Therapeutics

Arterial disease is one of the most common causes of death and disability, afflicting more than 15 million Americans. Although therapeutic advances and surgical techniques have decreased mortality, many survivors eventually succumb to death due to ischemia, which is the death of tissue and cells due to the lack of oxygen. Photon Therapeutics uses photosynthetic therapy to reverse nutrient and oxygen imbalance in ischemic tissue, starting with ischemic wound care. Photon Tx consists of a very strong clinical and scientific advisory team with proof-of-concept data and is looking for a CEO/business advisor to develop a biological platform company.

Center Pharm

Wolfram Syndrome is an orphan disease that has no treatment. Wolfram Syndrome is caused by mutations in wolframin, a protein that is necessary for normal function in cells, by binding to and preventing cleavage of neuronal calcium sensor 1 (NCS1). Center Pharm's drug candidate targets the cleavage site of NCS1. The drug will stabilize NCS1 levels and maintain normal cell functions to delay disease progression.

Instanosis

Detecting and quantifying very low concentrations of disease biomarkers is important for the diagnosis and management of many disease conditions in their early phases. Technologies to detect low concentrations of biomarkers are only available in the advanced research or central clinical laboratories, due to high technology complexity and costs causing significant delay in reaching correct diagnosis. Instanosis testing platform enables ultrasensitive, low-cost and rapid quantitation of disease biomarkers. This platform has many applications in multiple instances, where rapid, convenient and ultra-sensitive biomarker detection is crucial for disease detection and treatment. The lead application is the ultrasensitive detection of SARS-CoV-2 antigen in the community setting using smartphones. Current diagnostic gold standard for SARSCoV- 2 is rRT-PCR, which requires expensive extraction instrument, thermocycler, facilities and trained operators to conduct and hours or days to turn around results.

TSLP Therapeutics

Inflammatory diseases are often treated with immunomodulatory drugs which can result in severe side effects due to their systemic administration. This technology is a vitamin D analog which can be administered topically, therefore reducing systemic side effects. The drug works by triggering release of a regulatory cytokine from the skin and decreasing T cell activation which is involved in many inflammatory disorders.

Stork AI

Stork.ai is leveraging its strong foundations in reproductive medicine, big data, and artificial intelligence to create next-generation fertility products that ultimately help people have babies. It is commercializing a decision assessment tool comprised of patent-pending, AI-based software (“STORK”) that reliably assesses embryo (blastocyst) quality. STORK was developed using a proprietary, multi-focal embryo image dataset from Weill Cornell’s Center for Reproductive Medicine. STORK can also predict genetic defects such as aneuploidy, which involves an abnormal number of chromosomes in the embryo.

HIV-Rev Discovery

Human Immunodeficiency Virus (HIV) is a deleterious virus that attacks white blood cells (Specifically CD4 T cells) that fight infection, compromising the immune system and it's ability to fight infection. Untreated, HIV reduces the number of CD4 cells (T cells) in the body - the damage to the immune system makes it increasing difficult for the body to fight off infections and other diseases. Eventually, those infected with HIV develop Acquired Immunodeficiency Syndrome (AIDS), where infections or cancers take advantage of a very weak immune system, including infections that could otherwise be adequately defended against. There is no effective cure for HIV; it can only be managed by antiretroviral therapy (ART). Thus, there is a large unmet clinical need for a cure for HIV.

TRIC Robotics

Mucosinix Pharm

Mucosinix has a new class of antibiotics which have not been shown to trigger resistance in MRSA culture. This new antibiotic class shows promise as a treatment for multidrug resistant microbes.

AquaROS

Researchers at Stanford have developed a new water-based disinfectant with the potential to destroy a wide variety of pathogens and significantly improve healthcare settings. AquaROS, a novel and broad-spectrum disinfectant, is based on the formation of micron-sized water droplets that cause the spontaneous generation of highly reactive oxidant species (ROS). Access to safe and effective disinfecting solutions like AquaROS is more critical than ever – in the U.S. approximately the same number of people die from healthcare-associated infections (HAIs) as from AIDS, breast cancer and auto accidents combined. Inexpensively produced by atomizing water, the new disinfectant has been shown to outperform other commercial methods at inactivating Salmonella typhimurium and E. coli. Based on these and other promising results, the researchers anticipate AquaROS can kill bacteria, fungi, mycobacteria and bacterial spores on critical surfaces such as medical instruments.

smartHER

University of California, Irvine

smartHER is a mixed reality (MR/AR)-based medical device company focused on developing innovative solutions for gynecologic procedures, with an initial focus on rehauling how MRI scans are utilized for uterine fibroid removal. The company is spinning out of Weill Cornell Medicine (WCM) where it has gained significant traction by developing a MVP. It has received multiple awards for its novel product design, established strategic partners in several relevant domains (e.g., women med device, cloud computing, and MR software), and is in the process of validating the technology through a clinical study. smartHER is looking to hire its inaugural Chief Executive Officer (CEO).

Velox Biosystems

Velox Biosystems plans to develop and launch a rapid diagnostic product for urinary tract infections (UTI), a problem that affects nearly 50 percent of the population at least once in their lifetime. This decision follows the startup’s completion of a recent clinical feasibility test that yielded impactful clinical data for the company to move forward with the next steps in development. Velox Biosystems has created an ultra sensitive rapid detection system that provides for no or minimal sample processing, high throughput scanning of large sample volumes, with single target sensitivity and unprecedented speeds. Utilizing a digital droplet molecular detection platform, we are developing a point of care diagnostic device to address critical unmet needs in the UTI, liquid biopsy, and sepsis spaces. Total available market of over $1 Billion.

HL BioTherapeutics

George Washington University

HL BioTherapeutics aims to apply our unique immunotherapy platform that functions like a T cell receptor, to treat multiple types of solid and liquid cancers. The scientific founders, Catherine Bollard and Eric Yvon, have clinical and technical experience in designing and delivering novel immunotherapies to patients. The advantage of the HL BioTherapeutics platform is the extremely high specificity for tumors due to targeting of a specific MHC-displayed peptide from SSX2 protein. This targeting platform may be commercialized as an engineered T cell or NK cell, or as a therapeutic antibody. Our most advanced preclinical data uses T cell therapy for acute myeloid leukemia.

Andluca Technologies

Princeton University

Andluca Technologies designs transparent, thin-film power sources that convert ultraviolet light into useful energy at the point of use. These flexible power sources can conform to any shape and disappear into their environment to enable discreet, wireless operation of smart glass. Beyond buildings, our technologies are unlocking new functionalities in the automobile, aviation, military, eyewear, health and IoT sectors. Andluca Technologies was established in 2017 following over 12 years of research on light-responsive films by Professor Lynn Loo and her team at the Organic and Polymer Electronics Laboratory at Princeton University.

Theranostec

University of California, Davis

Theranostec have developed a novel, nanoparticle treatment platform allowing for targeted and effective chemotherapy, which can be enhanced with phototherapy, while also lowering toxicity.

Pearl Bio

Pearl Bio is an early-stage venture pioneering design and production of next-generation therapeutics and biomaterials for medical applications and beyond. Biology is constrained to the 20 natural amino acids, limiting the ability to site-specifically modify therapeutic proteins to improve half-life, tissue targeting, or assembly. In contrast, chemical synthesis of therapeutics enables access to greater functional diversity, but template-directed synthesis is challenging. Pearl Bio unites the precision of biology with the unlimited diversity of chemistry in a transformative platform that produces therapeutics and biomaterials with tunable properties for applications in oncology, immunology, and rare disease.

DeckTherapeutics

Columbia University

THDG3 represents a novel, patent protected omega-3 diglyceride emulsion developed by Dr. Deckelbaum’s laboratory at Columbia University. Acute injection of THDG3 emulsion following stroke leads to a marked reduction in brain tissue death (up to 90%, demonstrated in 6 rodent models), with associated preservation and recovery of both short and long term neurofunctional outcomes. Due to the high risk profile and short window of administration, less than 8% of stroke patients receive treatment with t-PA, the current standard of treatment for stroke. DeckTherapeutics is currently developing THDG3 emulsion as a drug candidate for standard emergency treatment for stroke, a global unmet need, with phase 2a trials planned in 2021.

My Gene Counsel

My Gene Counsel has created scalable, digital technology that pairs specific genetic test results with accurate, continuously updating information for clinicians and consumers. By helping patients and doctors become aware of the implications of genetic testing results, My Gene Counsel can help improve patients' lives and avoid unnecessary risky medical procedures.

Apeiros Bioscience

Carnegie Mellon University

Our goal is to develop a new cancer drug that is an antibody drug conjugate (ADC). It targets the pi subunit of the Gamma Aminobutyric Acid Receptor (GABRP) that is aberrantly expressed in a broad range of solid tumors. The target was discovered by the Pusztai lab and a provisional patent application has been submitted. We will use the Blavatnik Fund to perform affinity maturation, generate humanized anti-GABRP antibody conjugated to emtansine and assess the anti-tumor activity in vitro and in vivo.

ERLY Antivirals

Our lab has developed novel broad-spectrum antivirals for treatment of all nine human and several animal herpesviruses that overcomes drug resistance. We have shown that the pressurized state of the viral packaged genome is a target for antiviral therapies. This pressurized DNA state in herpesvirus capsid shell (exerting tens of atmospheres of pressure) is responsible for DNA ejection into a cell nucleus, causing infection. Several lead compounds that "turn off" capsid pressure and block viral genome ejection into a cell have demonstrated superior efficacy and safety in testing conducted at the NIH/NIAID. Although high activity has been shown with all human herpesviruses and several animal herpesviruses, our focus will be on treatment of human cytomegalovirus and MDV (Marek’s disease virus in poultry). For HCMV treatment, the market is dominated by generics, such as ganciclovir and foscarne, that have low efficacy and safety profiles. For MDV, no treatments are available.

SomaTx Design

KneeMo addresses problems associated with musculoskeletal disorders including sports related injuries and chronic disease such as osteoarthritis (OA). The potential market is substantial since musculoskeletal disorders affect more than one out of every two persons in the United States over age 18 and three out of four over age 65. Osteoarthritis alone accounts for 242 million people in the world who live with activity limiting symptoms. Pharmaceuticals, often used to alleviate the musculoskeletal pain come with side effects that can include addiction. KneeMo takes a novel mechanical approach to engage multimodal sensory pathways that signal pain using cutaneous mechanical stimuli (e.g., vibration) where over stimulation in one mode of the system (e.g., vibration) can gate response in other modalities (e.g. pain). KneeMo was shown in a placebo controlled clinical trial to provide an effective and safe alternative to pharmacological interventions to reduce pain and enhance function.

Rarebase Therapeutics